Background & Method: In this ongoing research, it is aimed to investigate the synthesis,
structure identification and effects on urokinase-type plasminogen activators (uPA) and its receptor
levels of 4-(3H-imidazo[4,5-b]pyridin-2-yl)-N-substituted benzamide and benzamidine derivatives.
uPA levels obtained from 4b and 7d administration were similar to 5-FU (5-fluorouracil) for colorectal
carcinoma cells (p<0.05). 4b and 7d significantly reduced uPAR (urokinase-type plasminogen activator
receptor) levels on both cell lines (p<0.05).
Conclusion: uPAR levels obtaining from 4b and 7d administration were similar to 5-FU for both cell
lines colorectal (Colo205, CCL-222) and hepatocellular (HepG2, CCL-23) carcinoma cells (p<0.05).
Keywords: Imidazopyridine, benzamide, benzamidine, urinary plasminogen activator, uPAR, upamostat.
Rights & PermissionsPrintExport